

Item No.	Bureau	Subject
1	Wireless Telecommunications	Title: 2000 Biennial Regulatory Review Spectrum Aggregation Limits for Commercial Mobile Radio Services (WT Docket No. 01-14). Summary: The Commission will consider a Report and Order concerning its reexamination of the need for the Commercial Mobile Radio Services spectrum aggregation limits and the cellular cross-interest rule.
2	Mass Media	Title: Rules and Policies Concerning Multiple Ownership of Radio Broadcast Stations in Local Markets; and Definition of Radio Markets (MM Docket No. 00-244). Summary: The Commission will consider a Notice of Proposed Rule Making concerning whether to undertake a comprehensive examination of its rules and policies of local radio ownership.
3	Mass Media	Title: Review of the Commission's Rules and Policies Affecting the Conversion To Digital Television (MM Docket No. 00-39). Summary: The Commission will consider a Memorandum Opinion and Order on Reconsideration concerning its periodic review of the progress of the conversion to digital television.
4	Common Carrier	Title: Performance Measurements and Standards for Unbundled Network Elements and Interconnection; Performance Measurements and Reporting Requirements for Operations Support Systems, Interconnection, and Operator Services and Directory Assistance (CC Docket No. 98-56); Deployment of Wireline Services Offering Advanced Telecommunications Capability (CC Docket No. 98-147); and Petition of Association for Local Telecommunications Services for Declaratory Ruling (CC Docket Nos. 98-147, 96-98, 98-141). Summary: The Commission will consider a Notice of Proposed Rule Making concerning the establishment of national performance measurements and standards for unbundled network elements and interconnection.
5	International	Title: Review of Commission Consideration of Applications under the Cable Landing License Act (IB Docket No. 00-106). Summary: The Commission will consider a Report and Order concerning its policies, rules and requirements for Cable Landing Licenses.

Additional information concerning this meeting may be obtained from Maureen Peratino or David Fiske, Office of Media Relations, telephone number (202) 418-0500; TTY 1-888-835-5322.

Copies of materials adopted at this meeting can be purchased from the FCC's duplicating contractor, Qualex International at (202) 863-2893; Fax (202) 863-2898; TTY (202) 863-2897. These copies are available in paper format and alternative media, including large print/type; digital disk; and audio tape. Qualex International may be reached by e-mail at qualexint@aol.com.

This meeting can be viewed over George Mason University's Capital Connection. The Capitol Connection also will carry the meeting live via the

Internet. For information on these services call (703) 993-3100. The audio portion of the meeting will be broadcast live on the Internet via the FCC's Internet audio broadcast page at <http://www.fcc.gov/realaudio/>. The meeting can also be heard via telephone, for a fee, from National Narrowcast Network, telephone (202) 966-2211 or fax (202) 966-1770. Audio and video tapes of this meeting can be purchased from Infocus, 341 Victory Drive, Herndon, VA 20170, telephone (703) 834-0100; fax number (703) 834-0111.

Federal Communications Commission.

Magalie Roman Salas,
Secretary.

[FR Doc. 01-28008 Filed 11-2-01; 2:58 pm]

BILLING CODE 6712-01-M

FEDERAL COMMUNICATIONS COMMISSION

Sunshine Act Meeting; A Closed Commission Meeting, Thursday, November 8, 2001

November 1, 2001.

The Federal Communications Commission will hold a Closed Meeting on the subject listed below on Thursday, November 8, 2001, following the Open Meeting, which is scheduled to commence at 9:30 a.m. in Room TW-C305, at 445 12th Street, SW., Washington, DC.

Item No.	Bureau	Subject
1	General Counsel	Title: Commission Internal Processes. Summary: The Commission will discuss possible changes to its internal processes.

This item is closed to the public because it concerns internal practices. (See 47 CFR Sec. 0.603(b)).

The following persons are expected to attend:

- Commissioners and their Assistants
- The Secretary
- General Counsel and members of her staff

Action by the Commission November 1, 2001. Commissioners, Powell Chairman; Abernathy, Copps and

Martin voting to consider these matters in Closed Session.

Additional information concerning this meeting may be obtained from Maureen Peratino or David Fiske, Office of Media Relations, telephone number (202) 418-0500; TTY 1-888-835-5322.

Federal Communications Commission.

Magalie Roman Salas,
Secretary.

[FR Doc. 01-28009 Filed 11-2-01; 2:58 pm]

BILLING CODE 6712-01-M

FEDERAL COMMUNICATIONS COMMISSION

Performance Review Board

As required by the Civil Service Reform Act of 1978 (Pub. L. 95-454), Chairman Michael K. Powell appointed the following executives to the Performance Review Board: Renee Licht, Jane Mago, Mary Beth Richards, and David Solomon.

Federal Communications Commission.

Magalie Roman Salas,

Secretary.

[FR Doc. 01-27782 Filed 11-5-01; 8:45 am]

BILLING CODE 6712-01-P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 30, 2001.

A. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166-2034:

1. *Tri-State Financial Services, Inc.*, Memphis, Tennessee; to become a bank holding company by acquiring 100 percent of the voting shares of Tri-State Bank of Memphis, Memphis, Tennessee.

Board of Governors of the Federal Reserve System, October 31, 2001.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 01-27772 Filed 11-5-01; 8:45 am]

BILLING CODE 6210-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01D-0432]

Draft Guidance for Industry on the Evaluation of the Effects of Orally Inhaled and Intranasal Corticosteroids on Growth in Children; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Evaluation of the Effects of Orally Inhaled and Intranasal Corticosteroids on Growth in Children." The Division of Pulmonary and Allergy Drug Products is providing guidance to industry regarding the design, conduct, and evaluation of clinical trials to evaluate the effects of orally inhaled and intranasal corticosteroids on growth in children. This action is important because of recently implemented class labeling of these products with regard to their impact on growth in children. An assessment of the available data supporting the class labeling action has led to recommendations that all drug products of this class be tested by means of a "growth study." The recommendations in this document can provide adequate and well-controlled data that is consistent among drug products and can be included in product labeling.

DATES: Submit written or electronic comments on the draft guidance by February 4, 2002. General comments on agency guidance documents are welcome at any time.

ADDRESSES: Submit written requests for single copies of the draft guidance to the Division of Drug Information (HFD-240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the draft guidance to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit

electronic comments to <http://www.fda.gov/dockets/ecomments>. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT:

Sandy Barnes, Center for Drug Evaluation and Research (HFD-570), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1050.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a draft guidance for industry entitled "Evaluation of the Effects of Orally Inhaled and Intranasal Corticosteroids on Growth in Children." This draft guidance has been developed by the Division of Pulmonary and Allergy Drug Products, in consultation with the Division of Metabolic and Endocrine Drug Products, to provide guidance in the design, conduct, and evaluation of clinical studies to assess the effects of orally inhaled and intranasal corticosteroids on linear growth.

On July 30 and 31, 1998, the Pulmonary and Allergy Drugs Advisory Committee and the Metabolic and Endocrine Drugs Advisory Committee were jointly convened to discuss the implications of findings in previous clinical studies that indicated that inhaled corticosteroids may, as a class of compounds, affect linear growth in pediatric patients. The joint committees agreed that data were sufficient to justify inclusion of a precautionary statement in the labeling for this class of compounds, but the data were inadequate to precisely determine the decrement in growth velocity resulting from the use of these drug products. Members of the joint committees recommended that companies filing new drug applications for all newly approved corticosteroid products conduct further studies, as post-approval phase 4 commitments, to assess the effects of nasally and orally inhaled corticosteroids on growth velocity in prepubertal children.

The draft guidance provides general recommendations for the design and conduct of a "growth study." The Division of Pulmonary and Allergy Drug Products endorses these recommendations to encourage the collection of other evidence that will consistently and accurately describe the effects of intranasal and orally inhaled corticosteroids on growth velocity in children.

This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115).